We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Implementing New Data and Evolving Standards in HER2-Negative Breast Cancer: Expert Strategies on the Expanding Role of Targeted Therapy.
- Authors
Arun, Banu
- Abstract
Targeting BRCA mutations with PARP inhibitors can increase progression-free survival in women with metastatic breast cancer who have these mutations. Unfortunately, this type of therapy has not yet been shown to improve survival. Using PARP inhibitors earlier in the disease process may significantly delay the time to recurrence.
- Subjects
CONTINUING education units; BRCA genes; DRUG resistance in cancer cells; CANCER relapse; BREAST tumors; ENZYME inhibitors; ANTINEOPLASTIC agents; MONOCLONAL antibodies; ADJUVANT chemotherapy; ONCOGENES; DNA repair; GENETIC mutation; PROGRESSION-free survival; TIME; PHARMACODYNAMICS
- Publication
Journal of Managed Care Medicine, 2024, Vol 27, Issue 2, p4
- ISSN
1094-1525
- Publication type
Article